若生智能
Drug Database
MM

MMR + varicella zoster vaccine (MMRV zoster vaccine)

✓ Approved

GSK · 疫苗 · 疫苗

什么是 MMR + varicella zoster vaccine？

MMR + varicella zoster vaccine 是一种疫苗，由GSK研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名MMRV zoster vaccine
公司GSK
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, GSK

治疗适应症

MMR + varicella zoster vaccine 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsSalmonellosis✓ Approved
Infections and infestationsMeasles✓ Approved
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedJournal of cancer research and clinical oncology2026-06-13

Phenotypic heterogeneity in carriers of a pathogenic MSH2 variant: implications for the diagnosis of Lynch syndrome.

Apuhan Tuna T, Demir Oguzhan O, Sagnak Yilmaz Zeynep Z, Karaman Elanur E et al.

Lynch syndrome is an inherited cancer predisposition syndrome caused by germline pathogenic variants in mismatch repair (MMR) genes and is primarily associated with colorectal and endometrial cancers. Classically, Lynch syndrome-associated tumors exhibit microsatellite instability (MSI) and loss of MMR protein expression on immunohistochemistry (IHC); therefore, MSI and IHC are routinely used in screening algorithms to support diagnostic evaluation. ; Methods: In this study, we present the molecular and pathological characteristics of four cases from three unrelated families carrying the same MSH2 variant [c.70C > T (p.Gln24Ter)], interpreted as pathogenic, who were diagnosed with breast and colorectal cancer. MSI analysis and MMR protein expression were evaluated in available tumor tissues. ; Results: Preserved MMR protein expression was observed in three cases, and two cases were microsatellite stable (MSS), whereas only one case demonstrated loss of MMR protein expression and an MSI-high phenotype consistent with the classical Lynch syndrome profile. These findings suggest that individuals carrying the same MSH2 variant may exhibit heterogeneous tumor-level MMR/MSI phenotypes. Early truncating variants in MSH2 may allow partially functional protein production via alternative translation initiation, potentially limiting complete loss of MMR function. Variability in somatic second-hit mechanisms and tumor-specific molecular pathways may also contribute to this heterogeneity. ; Conclusion: In conclusion, Lynch syndrome tumor biology may be more heterogeneous than expected, and MSI and IHC should not be interpreted in isolation as exclusionary tests for an underlying germline MMR variant, but rather as markers of tumor-level biological consequences. Therefore, germline findings, tumor characteristics, and family history should be evaluated together in Lynch syndrome diagnosis and risk assessment.

PMID 42286372
阅读全文 →
PubMedBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026-06-13

[Joint trajectories and evolution patterns of direct and indirect maternal mortality across 204 countries from 2000 to 2021].

Zhou Yi Y, Cheng Zhao Z, Feng Xinglin X

To identify joint trajectory patterns of direct and indirect maternal mortality ratios (MMR) at the country level from 2000 to 2021, and to compare phase-specific changes during the millennium development goals (MDG, 2000 to 2015) and the sustainable development goals (SDG, 2015 to 2021) periods, as well as differences in health system and policy environments across trajectory groups. Data on maternal mortality among women aged 15-49 years in 204 countries and territories from 2000 to 2021 were obtained from the Global Burden of Disease (GBD) Study. Direct cause MMR and indirect cause MMR at five time points (2000, 2005, 2010, 2015, and 2021) were jointly analyzed using longitudinal K-means clustering (k=2-6). The optimal number of clusters was determined by the Calinski-Harabasz (CH) index. Based on the clustering results, a piecewise linear mixed effects model with random intercepts was fitted with a knot in 2015 to estimate the baseline intercept in 2000 and period-specific slopes for the MDG and SDG phases. For 2021, health system and policy-related indicators, including antenatal care coverage (≥4 visits, ANC4), proportion of women with a demand for contraception that are using a modern method, cesarean section rate, female human immunodeficiency virus (HIV) prevalence, in facility delivery rate, skilled birth attendance, and an abortion legality index were compared across clusters using the Kruskal-Wallis H test. All tests were two-sided, and P < 0.05 was considered statistically significant. The CH index peaked at k=3 (CH=342.63), classifying the 204 countries and territories into three joint trajectory clusters: high burden (n= 66), medium burden (n=88), and low burden (n=50). In 2021, direct MMR was 334.6 (95%CI: 282.5- 386.7), 65.6 (95%CI: 50.4-80.7), and 5.4 (95%CI: 3.7-7.0) per 100 000 live births in the high, medium, and low burden clusters, respectively; indirect MMR was 33.6 (95%CI: 27.9-39.2), 18.2 (95%CI: 13.5-22.9), and 0.9 (95%CI: 0.6-1.3) per 100 000 live births, respectively. The piecewise mixed effects model showed significant declines in direct MMR during the MDG period in all clusters (slopes: -0.020, -0.016, and -0.036; P < 0.001), whereas declines slowed and became non-significant during the SDG period (-0.011, 0.011, and -0.006; P > 0.05). For indirect MMR, modest increases were observed during the MDG period in the high and medium burden clusters (0.029 and 0.015; P < 0.05), with no significant change in the low burden cluster (P > 0.05). During the SDG period, indirect MMR increased markedly in the medium burden cluster (slope: 0.121; 95%CI: 0.092-0.151; P < 0.001), while remaining broadly stable in the high and low burden clusters (P > 0.05). Health system and policy indicators differed significantly across the clusters (P < 0.001): the high burden cluster showed lower ANC4 coverage, lower in facility delivery and skilled birth attendance, lower demand for contraception satisfied by modern methods, and higher female HIV prevalence; the medium burden cluster achieved near universal in facility delivery and skilled birth attendance but had a higher cesarean section rate; the low-burden cluster generally showed more favorable indicator profiles and a higher abortion legality index. Distinct joint trajectories of direct and indirect maternal mortality were observed globally from 2000 to 2021. While reductions in direct maternal mortality were substantial during the MDG era, progress broadly slowed and plateaued during the SDG era. Meanwhile, the pronounced rise in indirect maternal mortality in medium-burden countries during the SDG period suggests potential structural risk accumulation even when overall MMR appears stable. Incorporating joint direct-indirect trajectories into routine monitoring may facilitate stage and cluster specific prioritization of maternal health interventions.

PMID 42287043
阅读全文 →
PubMedInternational journal of surgical pathology2026-06-13

ARID1A-Retained and SMARCA4-Aberrant Gastric Solid-Type Poorly Differentiated Adenocarcinoma and Prognosis: A Retrospective Cohort Study.

Umekita Shinya S, Kiyozawa Daisuke D, Kawatoko Shinichiro S, Sasaki Taisuke T et al.

AimsOur study investigated the clinical and pathological features of gastric solid-type poorly differentiated adenocarcinoma (PDA) along with the prognostic significance of ARID1A (AT-rich interactive domain 1A), SMARCA4, and epithelial-mesenchymal transition (EMT) markers in it.MethodsWe retrospectively evaluated 116 patients with primary gastric solid-type PDA, and patients were categorized according to deficient or proficient mismatch repair (MMR) status (51 and 65 patients, respectively). The expression of ARID1A, SMARCA4, and EMT markers (E-cadherin, β-catenin, vimentin, and SNAI1) was analyzed via immunohistochemistry, and the levels were assigned to the aberrant/retained or normal expression groups. The associations between the expression of ARID1A, SMARCA4, and EMT markers, clinicopathological characteristics, and prognostic impact were examined.ResultsProficient MMR was associated with ARID1A-retained status (P < .001), negative E-cadherin and β-catenin, and positive SNAI1 (P = .033, P = .003, and P = .008, respectively) in contrast to deficient MMR. Log-rank analysis revealed that the combination of ARID1A-retained and SMARCA4-aberrant status indicated significantly lower disease-free survival and overall survival rates than ARID1A-aberrant and SMARCA4-retained group (P < .001, P < .001, respectively). Multivariate analysis revealed that the combination of ARID1A-retained and SMARCA4-aberrant status was an independent indicator of unfavorable prognosis (hazard ratio = 4.784, P < .001).ConclusionsARID1A-retained status and expression of aberrant EMT markers (E-cadherin, β-catenin, and SNAI1) are more frequently observed in proficient-MMR in solid-type PDA. ARID1A-retained and SMARCA4-aberrant status can be considered a useful indicator of unfavorable prognosis in gastric solid-type PDA.

PMID 42286911
阅读全文 →
PubMedMedical molecular morphology2026-06-13

Integration of L1CAM and β-catenin immunohistochemistry for prognostic risk stratification of endometrial carcinoma: a practical approach for resource-limited settings.

Eldegwi Sara S, Gadelhak Basma B, Bassiouny Nadia N, Fawzy Mohamed M et al.

Accurate prognostic stratification of endometrial carcinoma (EC) remains challenging in resource-limited settings lacking molecular sequencing. We investigated whether immunohistochemical (IHC) assessment of combined L1CAM/β-catenin expression, integrated with mismatch repair (MMR) status and p53 expression, could refine prognostic risk stratification in EC in absence of POLE sequencing. A retrospective cohort study evaluated 140 surgically staged EC cases for L1CAM, β-catenin MMR, and p53 IHC expression with clinicopathological correlation. Survival analysis was performed on 111 cases (median follow up:38 months). L1CAM and β-catenin demonstrated mutually exclusive expression patterns (27.1% and 6.4% respectively; 66.5% double negative). L1CAM + tumors demonstrated significantly worse disease specific survival (DSS) (HR:4, 95%CI: 1.6-9.9) and disease-free survival (DFS) (HR:4.9, 95%CI: 2.2-11.4), compared to double-negative (64.5% vs 90.3% DSS, 41.9% vs 12.5% relapse rate). β-catenin alone didn't predict outcome but contributed to prognostic refinement when combined with L1CAM status. This prognostic gradient persisted in the pMMR/p53wt subgroup (L1CAM + mean DFS: 21.7 months vs double-negative: 69.6 months; p ≤ 0.001). The combined L1CAM/β-catenin IHC profile categorized patients into prognostically distinct categories and offers pragmatic prognostic refinement, particularly for pMMR/p53wt tumors in centers lacking POLE sequencing. This approach doesn't replace comprehensive molecular testing and requires prospective validation before clinical implementation.

PMID 42286151
阅读全文 →
PubMedVaccine2026-06-13

HPV vaccine: Influencing peer recommendations through information provision at no-cost vaccine clinics.

Ky Samantha L SL, Coblentz Evan G EG, Swanson Emma E, Shah Rhea R et al.

Human papillomavirus (HPV) is the most common sexually transmitted infection among people ages 15-24 years in the U.S. However, many individuals remain unvaccinated against HPV. Recommendations from friends and family have been shown to improve vaccine uptake and should be encouraged. This study aimed to determine if the provision of vaccine-related information would change the likelihood of recommending the HPV vaccine to their peers. Furthermore, we examined characteristics associated with a positive change. Participants were recruited at two no-cost vaccine clinics on a university campus in September and October 2024. Through a one-time, voluntary, online survey, participants were asked how likely they were to recommend the HPV vaccine to a family or friend on a scale from 1 (very unlikely) to 5 (very likely). This question was repeated after they were provided with a list of diseases that are prevented by the HPV vaccine. We conducted dependent samples t-tests to determine if there was a change in recommendation scores before and after information provision. We also conducted bivariate (chi-square and independent t-tests) and multivariable (logistic regression) analyses to examine factors associated with a positive change versus no/negative change. The final sample (n = 556) were majority White (n = 310, 55.8%), female (n = 331, 59.5%), and college students (n = 480, 86.5%). The average post-information provision (Mean = 4.21; SD = 0.95) recommendation score was significantly higher than the pre-information provision (Mean = 3.87; SD = 1.031) recommendation score (t = -11.37; p < 0.001). In multivariable logistic regression analyses, there was a statistically significant positive change in recommendation score with younger age (aOR = 0.98, 95% CI = 0.95-1.00) and lower vaccine confidence (aOR = 0.50, 95%CI = 0.36-0.68). This indicates that targeted interventions to improve awareness of diseases prevented by the HPV vaccine could be particularly effective in populations that are younger or have lower vaccine confidence.

PMID 42284811
阅读全文 →
PubMedInternational immunopharmacology2026-06-13

Neoantigen-based multi-epitope vaccine designing against glioblastoma using reverse vaccinology and immunoinformatic approaches.

Din Miraj Ud MU, Ahmad Sajjad S, Liu Xiaohui X, Jiang Hui H et al.

One of the primary factors in the development of cancer is the accumulation of genetic mutations. Some of these genetic mutations result in the emergence of unique antigens called neoantigens. These neoantigens are perceived as non-self by T cells, making them prime targets for cancer vaccines. These neoantigen-based vaccines can elicit a promising immune response against the malignant cells. In the current research work, a computational approach was employed to design a multi-epitope vaccine for glioblastoma. A set of 126 neoantigens was retrieved from the CEDAR cancer epitopes database which yielded 446 epitopes. The epitopes were screened and 10 potential epitopes were selected to design a multi-epitope vaccine. GPGPG linkers were used for combining these epitopes, while adjuvants were connected to the vaccine via EAAAK and RVRR linkers to build the final construct of the vaccine. The physicochemical properties of the vaccine indicated that the designed vaccine is highly antigenic (0.7841 antigenicity score), non-allergenic, non-toxic, and also water soluble. Molecular docking assessed the interaction of the vaccine with MHC-I, MHC-II, and TLR-4, demonstrating strong binding affinities (-886.5 kcal/Mol, -1050.2 kcal/Mol, and - 1018.3 kcal/Mol, respectively). The docking results were further supported by the normal mode analysis and molecular dynamics simulation showing average RMSD values of 4.21 Å, 6.80 Å, and 5.68 Å for the three complexes, respectively. The in silico cloning of the vaccine into the bacterial plasmid (pET28a+) was carried out to enhance its expression achieving a GC content of 57.43 and a codon adaptation index of 1. The in silico immune simulation revealed that peak antigen levels (∼7.5 × 105 counts/mL at approximately day 50) elicited strong humoral and cellular immune responses, characterized by elevated IgM + IgG titers (∼2.8 × 105) and increased cytokine production, including IFN-γ (∼4.5 × 105), IL-2 (∼6.0 × 105), and TNF-α (∼1.2 × 105 ng/mL), indicating robust immune activation. These findings indicated that our designed vaccine could be a potential therapeutic candidate against glioblastoma. Further experimental research is required to validate the potential, efficacy, and safety of the designed vaccine.

PMID 42284765
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多MMR + varicella zoster vaccine